A recombinant multi-epitope peptide vaccine based on MOMP and CPSIT_p6 protein protects against Chlamydia psittaci lung infection

Li, Yumeng; Zheng, Kang; Tan, Yuan; Wen, Yang; Wang, Chuan; Chen, Qian; Yu, Jiangnan; Xu, Man; Tan, Manyi; Wu, Yimou

doi:10.1007/s00253-018-9513-4

Cited by 16 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results also show GrpE vaccination in the presence of FCA could induce readily detectable Th1 responses; however, there wasn't increased inflammation in response to the infection or reduced pathological changes of the infected site. FCA are known to enhance the immunogenicity of the immunogen, play an immune regulation role, and increase the immune effect of the antigen, which can modulate immune cells and enhance humoral and cellular immune responses in the host (22,46,47). So we conclude that the GrpE protein in the presence of FCA may induce protective Th1 immune response in mice and be considered as an effective vaccine against U. urealyticum infection.…”

Section: Discussionmentioning

confidence: 70%

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

et al. 2020

View full text Add to dashboard Cite

Nucleotide exchange factor (GrpE), a highly conserved antigen, is rapidly expressed and upregulated when Ureaplasma urealyticum infects a host, which could act as a candidative vaccine if it can induce an anti-U. urealyticum immune reaction. Here, we evaluated the vaccine potential of recombinant GrpE protein adjuvanted by Freund's adjuvant (FA), to protect against U. urealyticum genital tract infection in a mouse model. After booster immunization in mice with FA, the GrpE can induced both humoral and cellular immune response after intramuscular injection into BALB/c mice. A strong humoral immune response was detected in the GrpE-immunized mice characterized by production of high titers of antigen-specific serum IgG (IgG1, IgG2a, and IgG3) antibodies. At the same time, the GrpE also induced a Th1-biased cytokine spectrum with high levels of IFN-γ and TNF-α after re-stimulation with immunogen GrpE in vitro, suggesting that GrpE could trigger the Th1 response when used for vaccination in the presence of FA. Although GrpE vaccination in the presence of a Th1-type adjuvant-induced had readily detectable Th1 responses, there wasn't increase inflammation in response to the infection. More importantly, the robust immune responses in mice after immunization with GrpE showed a significantly reduced U. urealyticum burden in cervical tissues. Histopathological analysis confirmed that tissues of GrpE-immunized BALB/c mice were protected against the pathological effects of U. urealyticum infection. In conclusion, this study preliminarily reveals GrpE protein as a promising new candidate vaccine for preventing U. urealyticum reproductive tract infection.

show abstract

Section: Discussionmentioning

confidence: 70%

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Computational analysis for B-and T-cell epitopes within the Chlamydia MOMP have been performed for many different Chlamydia species 34,35 including C. pecorum 36 . These predictions identified B-cell and T-cell epitopes within both conserved and variable domains of the MOMP.…”

Section: Discussionmentioning

confidence: 99%

Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum

Phillips

Chaban

Olagoke

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Chlamydia infection and disease are endemic in free-ranging koalas. Antibiotics remain the front line treatment for Chlamydia in koalas, despite their rates of treatment failure and adverse gut dysbiosis outcomes. A Chlamydia vaccine for koalas has shown promise for replacing antibiotic treatment in mild ocular Chlamydia disease. in more severe disease presentations that require antibiotic intervention, the effect of vaccinating during antibiotic use is not currently known. This study investigated whether a productive immune response could be induced by vaccinating koalas during antibiotic treatment for Chlamydia-induced cystitis. plasma igG antibody levels against the C. pecorum major outer membrane protein (MoMp) dropped during antibiotic treatment in both vaccinated and unvaccinated koalas. post-treatment, igG levels recovered. the igG antibodies from naturally-infected, vaccinated koalas recognised a greater proportion of the MoMp protein compared to their naturally-infected, unvaccinated counterparts. furthermore, peripheral blood mononuclear cell gene expression revealed an up-regulation in genes related to neutrophil degranulation in vaccinated koalas during the first month post-vaccination. These findings show that vaccination of koalas while they are being treated with antibiotics for cystitis can result in the generation of a productive immune response, in the form of increased and expanded igG production and host response through neutrophil degranulation.

show abstract

“…Further, it has been demonstrated that multi-epitope combined vaccine induce stronger CTL responses compared to those induced by a single-epitope vaccine by enhancing cellular immunity and releasing immune tolerance [29]. The cellular and humoral responses generated by the multi-epitope vaccines are highly speci c with increased cytokines production [84][85][86]. A multi-epitope vaccine developed with such precautions can thus become a powerful tool in the battle against viral infections [87].…”

Section: Discussionmentioning

confidence: 99%

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

Deb

Basak

Kar

et al. 2020

Preprint

View full text Add to dashboard Cite

Chandipura vesiculovirus (CHPV) is a rapidly emerging pathogen responsible for causing acute encephalitis. Due to its widespread occurrence in Asian and African countries, this has become a global threat, and there is an urgent need to design an effective and non-allergenic vaccine against this pathogen. The conventional method of vaccine design involves large proteins or whole organism which leads to unnecessary antigenic load with increased chances of allergenic reactions. In addition, the process is also very time consuming and labour intensive. These limitations can be overcome by peptide-based vaccines comprising of short immunogenic peptide fragments that can elicit highly targeted immune responses, avoiding the chances of allergenic reactions, in a relatively shorter time span. The multi-epitope vaccine constructed using CTL, HTL and IFN-γ epitopes was able to elicit specific immune responses when exposed to the pathogen, in-silico. Not only that, Molecular Docking and Molecular Dynamics Simulation studies confirmed a stable interaction of the vaccine with the immune receptors. Several physicochemical analyses of the designed vaccine candidate confirmed it to be highly immunogenic and non-allergic. The computer-aided analysis performed in this study suggests that the designed multi-epitope vaccine can elicit specific immune responses and can be a potential candidate against CHPV.

show abstract

A recombinant multi-epitope peptide vaccine based on MOMP and CPSIT_p6 protein protects against Chlamydia psittaci lung infection

Cited by 16 publications

References 40 publications

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

Contact Info

Product

Resources

About